


PHARMACEUTICAL 2022

Atreca Inc. Rank 325 of 475







PHARMACEUTICAL 2022

Atreca Inc. Rank 325 of 475



The relative strengths and weaknesses of Atreca Inc. are analyzed with respect to the market average, including all of its competitors. We analyzed all variables having an effect on the Economic Capital Ratio.

The greatest strength of Atreca Inc. compared to the market average is the variable Property and Equipment, increasing the Economic Capital Ratio by 81% points. The greatest weakness of Atreca Inc. is the variable Net Income, reducing the Economic Capital Ratio by 138% points.

The company's Economic Capital Ratio, given in the ranking table, is -223%, being 53% points above the market average of -276%.

Input Variable	Value in 1000 USD
Assets, Current	122,370
Cost of Goods Sold	0
Intangible Assets	0
Liabilities, Current	16,899
Liabilities, Non-Current	0
Other Assets	34,672
Other Compr. Net Income	0
Other Expenses	4.0
Other Liabilities	28,229
Other Net Income	130
Property and Equipment	43,015
Research and Development	78,349
Revenues	851
Selling, General and Administrative Expense	31,954

Output Variable	Value in 1000 USD
Assets	200,057
Liabilities	45,128
Expenses	110,307
Stockholders Equity	154,929
Net Income	-109,326
Comprehensive Net Income	-109,326
Economic Capital Ratio	-223%